#132 Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy

Complicated UTIs just got a whole lot less complicated—or did they? Dr. Dana Bowers and Kyle Molina (@kcmolinaID) join Dr. Whitney Buckel to break down what’s new, what’s controversial, and what this means for your day‑to‑day antimicrobial decisions. Join us as we dig into the biggest updates, the evidence behind them, and the clinical pearls you won’t want to miss.

References:

Nelson Z, Aslan AT, Beahm NP, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement. JAMA Netw Open. 2024 Nov 4;7(11):e2444495.

Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. Published July 17, 2025. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/

Kadry N, Natarajan M, Bein E, Kim P, Farley J. Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections. Clin Infect Dis 2023;76(10:1768-1775. https://academic.oup.com/cid/article/76/10/1768/6980780

USCAST Oral cephalosporin STIC against S. aureus and E. coli meeting recording. https://www.youtube.com/watch?v=HieaVFAC08s

MacDougall C. A Cloudy Crystal Ball: Critically Assessing and Rethinking the Antibiogram. Clin Infect Dis. 2023;77(11):1501-1503. doi:10.1093/cid/ciad468

Koehl J, Spolsdoff D, Negaard B, et al. Cephalosporins for Outpatient Pyelonephritis in the Emergency Department: COPY-ED Study. Ann Emerg Med. 2025;85(3):240-248. doi:10.1016/j.annemergmed.2024.10.013

Dunne MW, Aronin SI, Das AF, et al. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023;76(1):78-88. doi:10.1093/cid/ciac704

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About

Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/)https://www.instagram.com/breakpointspodcast_sidp/?hl=en

Facebook: https://www.facebook.com/sidprx

LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Guests

sRakhB2muDUAAAAASUVORK5CYII=

Dr. Dana Bowers is an associate professor and infectious diseases specialist at Washington State University College of Pharmacy in Yakima, Washington. Her current research interests include gram-negative resistance, pharmacokinetics/pharmacodynamics, and the behavioral economics of antimicrobial stewardship

Kyle Molina is an Infectious Diseases and stewardship pharmacist at Scripps Health in San Diego, CA. His research related interest are long-acting lipoglycopeptides, real-world use of novel therapeutics to combat antimicrobial resistance, and antimicrobial PK/PD

Leave a Reply

Your email address will not be published. Required fields are marked *

Join the Conversation: Subscribe to Our Podcast for Exclusive Insights!

Founded in 1990, the Society of Infectious Diseases Pharmacists (SIDP) is dedicated to promoting the appropriate use of antimicrobials through education, training, research, and policy. 

PO Box 1488
Warrenville, IL 60555
(331) 248-7888
sidp@affinity-strategies.com

SIDP Logo

© 2024 Society of Infectious Diseases Pharmacists / PO Box 1488, Warrenville, IL 60555
(331) 248-7888 / sidp@affinity-strategies.com